The FDA approved the BRAF/MEK inhibitor combination encorafenib/binimetinib for 
patients with metastatic or inoperable melanoma with a BRAF V600E or V600K 
mutation. The approval was based on results of a phase III trial in which 
patients treated with the combination had a median progression-free survival of 
14.9 months, compared with 7.3 months in a control group that received 
vemurafenib alone.